Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 8/20 | 0.78 |
| ▸ | ABL1 | P00519 | 11/20 | 0.77 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.72 |
| ▸ | KDR | P35968 | 2/20 | 0.72 |
| ▸ | CSF1R | P07333 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28054441 | 0.93 | ABL1 (0.69) | KITABL1 | |
| SCHEMBL4099939 | 0.92 | KIT (0.67) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL16908401 | 0.91 | ABL1 (0.64) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL15498098 | 0.91 | KIT (0.82) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL4104547 | 0.88 | KIT (0.69) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL29856181 | 0.88 | KIT (1.00) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL4103102 | 0.88 | KIT (1.00) | KITABL1FGFR1KDRCSF1R | |
| SCHEMBL19317717 | 0.88 | ABL1 (0.84) | KITABL1FGFR1KDR | |
| SCHEMBL4112245 | 0.87 | ABL1 (1.00) | KITABL1FGFR1KDR | |
| SCHEMBL31620735 | 0.86 | KIT (1.00) | KITABL1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106632347-B | Preparation method of pyrrolopyrazine compound and salt thereof | 南京圣和药物研发有限公司 | 2021-09-10 | — | — | CN | disclosed |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| US-9255107-B2 | Heteroaryl alkyne compound and use thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-02-09 | — | — | US | disclosed |
| US-20150299202-A1 | HETEROARYL ALKYNE COMPOUND AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-10-22 | — | — | US | disclosed |
| EP-2927232-A1 | HETEROARYL ALKYNE COMPOUND AND APPLICATION THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2015-10-07 | — | — | EP | disclosed |
| EP-2024366-B1 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMA INC (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2896620-A1 | ALKYNYL HETEROAROMATIC RING COMPOUND AND APPLICATION THEREOF | Nanjing Sanhome Pharmaceutical Co., Ltd. (CN) | 2015-07-22 | — | — | EP | disclosed |
| US-20150152088-A1 | ALKYNYL HETEROAROMATIC COMPOUND AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| WO-2015014283-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | 南京圣和药业股份有限公司 (CN) | 2015-02-05 | — | — | WO | disclosed |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8278307-B2 | Monocyclic Heteroaryl compounds | ARIAD PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| EP-2024366-A2 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007133562-A2 | MONOCYCLIC HETEROARYL COMPOUNDS | ARIAD PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | KIT 813/4885ABL1 357/4885FGFR1 1012/4885 |
| US-20130005738-A1 | Monocyclic Heteroaryl Compounds | CYP3A43, CYP2F1, CYP11B2 | KIT 1003/4885ABL1 71/4885FGFR1 1199/4885 |
| US-20150299202-A1 | HETEROARYL ALKYNE COMPOUND AND USE THEREOF | ABL1, ALK, ABL2 | KIT 163/4885ABL1 1/4885FGFR1 61/4885 |
| US-20150152088-A1 | ALKYNYL HETEROAROMATIC COMPOUND AND USE THEREOF | ALK, CYP3A43, ALKBH3 | KIT 1066/4885ABL1 290/4885FGFR1 1342/4885 |
| US-20170369446-A1 | MONOCYCLIC HETEROARYL COMPOUNDS | CYP3A43, CYP2F1, CYP11B2 | KIT 1003/4885ABL1 71/4885FGFR1 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.